Literature DB >> 10794799

Genetic immunotherapy for cancer.

A Ribas1, L H Butterfield, J S Economou.   

Abstract

Genetic immunization refers to treatment strategies where gene transfer methods are used to generate immune responses against cancer. Our growing knowledge of the mechanisms regulating the initiation and maintenance of cytotoxic immune responses has provided the rationale for the design of several genetic immunization strategies. Tumor cells have been gene-modified to express immune stimulatory genes and are then administered as tumor vaccines, in an attempt to overcome tumor cell ignorance by the immune system. With the description of well-characterized tumor antigens, multiple strategies have been proposed mainly aimed at optimal tumor antigen presentation by antigen-presenting cells (APC). Among APC, the dendritic cells have been recognized as the most powerful cells in this class, and have become the target for introducing tumor antigen genes to initiate antitumor immune responses. The detailed knowledge of how the immune system can be activated to specifically recognize tumor antigens, and the mechanisms involved in the control of this immune response, provide the basis for modern genetic immunization strategies for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794799     DOI: 10.1634/theoncologist.5-2-87

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  3 in total

1.  Neural stem cell-based gene therapy for brain tumors.

Authors:  Seung U Kim
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 2.  Gene therapy imaging in patients for oncological applications.

Authors:  Iván Peñuelas; Uwe Haberkorn; Shahriar Yaghoubi; Sanjiv S Gambhir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

3.  The novel chicken interleukin 26 protein is overexpressed in T cells and induces proinflammatory cytokines.

Authors:  Anh Duc Truong; Boyeong Park; Jihye Ban; Yeong Ho Hong
Journal:  Vet Res       Date:  2016-06-16       Impact factor: 3.683

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.